drugset / Trial / NCT02799446

Effect of Reslizumab in Chronic Rhinosinusitis

NCT02799446

Phase 3 Unknown 30 enrolled Joshua S. Jacobs
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether Reslizumab is effective for the treatment of chronic sinusitis.

Timeline

Start
2016-06
Primary completion
2019-07
Completion
2019-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Reslizumab Monoclonal antibody 3 mg/kg Intravenous

Indications